What Is PACAP (Pituitary Adenylate Cyclase-Activating Peptide)? Benefits, Research & Safety

PACAP was first isolated in 1989 by Professor Akira Arimura and colleagues at Tulane University in New Orleans, Louisiana. The peptide was identified from ovine hypothalamic tissue extracts based on its ability to stimulate adenylate cyclase activity in rat anterior pituitary cell cultures — hence its name. The 38-amino-acid form (PACAP-38) was characterised first, followed shortly by the identification of the 27-amino-acid form (PACAP-27). The gene encoding PACAP (ADCYAP1) was subsequently cloned, revealing that PACAP is produced as a larger precursor protein (prepro-PACAP) that is processed to yield the mature peptides. The remarkable evolutionary conservation of PACAP became apparent as homologues were identified across vertebrates from fish to humans, with sequence identity exceeding 90%. This extraordinary conservation — unusual even among neuropeptides — pointed to essential physiological functions. Throughout the 1990s and 2000s, the three PACAP receptors (PAC1, VPAC1, VPAC2) were identified and characterised, each with distinct tissue distributions and signalling properties. The PAC1 receptor, which shows high selectivity for PACAP over VIP, was found to be particularly abundant in the brain. Research expanded rapidly into diverse areas including neuroprotection (demonstrating that PACAP could protect neurons from a wide range of insults), stress biology (revealing PACAP's role as a stress-response mediator), migraine (showing that PACAP infusion triggers migraine attacks), circadian regulation (establishing PACAP's role in light-dark cycle entrainment), and immune modulation (characterising its anti-inflammatory properties). The migraine field has been particularly productive, with anti-PACAP antibodies entering clinical trials as novel migraine preventive therapies, representing a direct translational application of basic PACAP research.